Hetero Group to invest Rs 1000 crore to expand pharma, specialist business in Andhra Pradesh
Andhra Pradesh: Drug maker Hetero Group will be investing Rs 1,000 crore to expand its pharmaceutical and specialist business in Andhra Pradesh, its Managaing Director Vamsi Krishna Bandi said on Saturday.
Speaking at Global Investors Summit 2023 here, he said post-Covid pandemic, more countries are looking at India as a partner of choice in pharmaceutical sector, and Andhra Pradesh is ideally placed to take advantage because of a well-established ecosystem.
"We are committed to Andhra Pradesh and will continue to expand our presence here. We'll be investing about Rs 1,000 crore in Andhra Pradesh over the next two years to grow our pharmaceutical and specialty business. This will generate an employment of a minimum of 3,000 people," he said.
Bandi further said the USD 2.5 billion pharma group employs over 10,000 people directly and indirectly in Andhra Pradesh, and supplies about 40 percent of global HIV medicines that are manufactured in the state.
Read also: Hetero Biopharma gets CDSCO panel nod to market, manufacture Tenecteplase
The Hetero Group is headquartered in Hyderabad, India. The company operates the Global Active Pharmaceutical business and Generic Formulations businesses with the support of 36+ manufacturing facilities, producing a wide range of APIs and FDFs across various therapeutic areas.
Besides the API business, the company established Hetero Healthcare in the country which is engaged in the marketing and distribution of branded generic medicines. It has a strong presence in India with 11 specialised marketing divisions.
Read also: FIRST: Hetero wins WHO Prequalification for generic version of Pfizer COVID drug Paxlovid
